1. Trends & External Forces

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Written by Posted on Less than 0 min read

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx.

Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers’ preparation.

To learn more, register for ConnectiveRx’s free webinar on December 11: The Perfect Storm? Patient Support Programming in 2025 and Beyond.

Read on for Chris’s insights.

Read more »

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Trends & External Forces

Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs (rerun)

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The article below highlights an underappreciated consequence of the Inflation Reduction Act’s inflation rebates for Medicare Part B drugs. Last night, I posted an updated analysis showing that the volatility […]
3 min read
0
  1. Trends & External Forces

2025 Brand Drug Challenges: A GoodRx Perspective

Today’s guest post is from Dorothy Gemmell, Chief Commercial Officer and President, Manufacturer Solutions, at GoodRx. Dorothy highlights five trends to watch in 2025. She then describes how GoodRx’s Cash Point-of-Sale Solution can help brands improve gross-to-net (GTN) while also making medications more affordable for patients. Click here to download the latest GoodRx data on […]
2 min read
0
  1. Trends & External Forces

Available for Preorder: The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fourteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. 9 chapters, 300+ pages, 163 exhibits, 600+ endnotes: There is nothing else available that comes close […]
3 min read
0
  1. Media & Marketing

How Payers Are Reacting to Insulin Price Changes

Today’s guest post comes from Nicole Mayer, Senior Analyst at MMIT. Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products. She also discusses MMIT’s […]
2 min read
0
  1. Trends & External Forces

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Click here to see the original post from December 2023. Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a […]
2 min read
0
  1. Trends & External Forces

Drug Channels Outlook 2024 (NEW Live Video Webinar)

It’s time for our most popular event of the year! Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. to […]
3 min read
0
  1. Data & Insights

Gross-to-Net Bubble Update: 2023 Pricing Realities at 10 Top Drugmakers

It’s time for Drug Channels’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes the following 10 companies: Bristol Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck, Novo Nordisk, Sanofi, Takeda, Teva, and UCB. You can find links to each company’s data below. These data remain inconvenient for drug pricing […]
2 min read
0
  1. Shopper & Customer

Best Practices for Successfully Transitioning a Patient Services Hub

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health Josh discusses challenges manufacturers may face when outsourcing patient support programs. He outlines a process that smoothly transitions hubs and minimizes disruptions for patients and healthcare providers. To learn more, download the 3-step guide to […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2024 Video Webinar Series

Drug Channel Institute is pleased to announce The Drug Channels 2024 Video Webinar Series. Join Dr. Adam J. Fein for three live video webinars during 2024. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. During these events, Dr. Fein will address the latest issues […]
2 min read
0
  1. Media & Marketing

Follow the 340B Prescription Dollar: How PBMs Profit from 340B Contract Pharmacies (Video)

In my recent The 340B Drug Pricing Program: Trends, Controversies, and Outlook video webinar, I provided an update on the economics of the 340B program, reviewed the multiple controversies surrounding the program’s operations, discussed state and federal legislation, and analyzed how the Inflation Reduction Act of 2022 (IRA) will alter the 340B market. In the video […]
2 min read
0
  1. Shopper & Customer

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Today’s guest post comes from Adam Stotts, SVP of Customer Success at AssistRx. Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. To learn about AssistRx’s digital intake solutions, download […]
2 min read
0
  1. Trends & External Forces

Why the IRA Will Encourage Part D Plans to Prefer High-List, High-Rebate Drugs (video)

In my recent Drug Channel Implications of the Inflation Reduction Act video webinar, I explained the intended and unintended consequences of the Inflation Reduction Act of 2022 (IRA) for the commercial market and drug channel participants. In the video excerpt below, I walk through a mathematical example to show why the IRA will encourage Part […]
2 min read
0
  1. Trends & External Forces

Who Will Pay for Prescription Drugs in 2032: Four Takeaways from the New Government Forecasts

The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently released the latest projections for U.S. spending on healthcare. (See links below.) These data provide the latest official look at how the Inflation Reduction Act (IRA) will affect U.S. healthcare spending. As you will see below, CMS projects that outpatient prescription drugs dispensed […]
2 min read
0
  1. Trends & External Forces

Mark Cuban: Five Ways that Big PBMs Hurt U.S. Healthcare–And How We Can Fix It

Today’s guest post comes from Mark Cuban, co-founder of the Mark Cuban Cost Plus Drug Company A few weeks ago, Mark participated in the White House Roundtable on Lowering Healthcare Costs and Bringing Transparency to Prescription Drug Middlemen. I found Mark’s comments to be intriguing and highly provocative, so I invited him to publish an […]
2 min read
0
  1. Trends & External Forces

Large Chains’ Position in 2025’s Part D Pharmacy Networks: Supermarkets Take the Lead in a Shrinking PDP Market

In Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market, I documented the Inflation Reduction Act’s (IRA) disruption to Medicare Part D prescription drug plans (PDPs). Today, we examine the seven largest retail chains’ participation in the 12 major 2025 Part D networks that the five largest plan sponsors will […]
3 min read
0
  1. Channel: Drug

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. Click here to see the original post. During Friday’s webinar, I’ll share some updated thoughts on biosimilars and PBM’s private label products. The Humira biosimilar market just took another step forward—but remains far from its ideal state. […]
2 min read
0
  1. Technology & Innovation

Transforming Medication Access with the Next Generation of Patient Support Services

Today’s guest post comes from Kelly Martin, Vice President of Product Management at CoverMyMeds. Kelly discusses the obstacles that patients face when attempting to access, afford, and adhere to specialty therapies. She describes how CoverMyMeds improves the patient experience by blending technology with human expertise and connection. Click here to learn about CoverMyMed’s next-generation patient […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, March 2024: My $0.02 of CarelonRx/Kroger & CVS, Provider-Owned Pharmacies, Shady AFPs, 340B Deception, and Lilly’s GLP-1 Ad

It’s finally spring in Philadelphia, home of Drug Channels. Along with sunshine and fine weather, the vernal equinox has ushered in a crop of new and noteworthy stories: What the CarelonRx/Kroger specialty pharmacy deal means for CVS Health Provider-owned specialty pharmacies expand in Medicare Payers are not keen on shady alternative funding programs (AFP) Hospitals’ […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s PAP – Patient Assistance & Access Programs

Informa Connect’s PAP – Patient Assistance & Access Programs March 19-21, 2024 Pre-Conference Workshops on March 18, 2024 Philadelphia Marriott Downtown in Philadelphia, PA Exclusive Offer – Be sure to use your exclusive promo code 24DC10 to save 10% off* of your registration. It is our responsibility as an industry to ensure patients have access […]
4 min read
0
  1. Trends & External Forces

NOW AVAILABLE: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

I am pleased to announce our new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, available for purchase and immediate download. Download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) HMP Global’s Drug Channels Institute releases ‘2024 Economic Report on U.S. Pharmacies and Pharmacy […]
3 min read
0
Next